Show simple item record

dc.contributor.authorBoon, Een_US
dc.contributor.authorValstar, MHen_US
dc.contributor.authorvan der Graaf, WTAen_US
dc.contributor.authorBloemena, Een_US
dc.contributor.authorWillems, SMen_US
dc.contributor.authorMeeuwis, CAen_US
dc.contributor.authorSlootweg, PJen_US
dc.contributor.authorSmit, LAen_US
dc.contributor.authorMerkx, MAWen_US
dc.contributor.authorTakes, RPen_US
dc.contributor.authorKaanders, JHAMen_US
dc.contributor.authorGroenen, PJTAen_US
dc.contributor.authorFlucke, UEen_US
dc.contributor.authorvan Herpen, CMLen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2019-03-05T16:39:54Z
dc.date.issued2018-07en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29909898en_US
dc.identifierS1368-8375(18)30164-7en_US
dc.identifier.citationOral Oncol, 2018, 82 pp. 29 - 33en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3140
dc.identifier.eissn1879-0593en_US
dc.identifier.doi10.1016/j.oraloncology.2018.04.022en_US
dc.description.abstractOBJECTIVES: In 2010, a new subtype of salivary gland cancer (SGC), (mammary analogue) secretory carcinoma (SC), was defined, characterized by the ETV6-NTRK3 fusion gene. As clinical behavior and outcome data of this histological subtype tumor are still sparse, we aimed to describe the clinicopathological course and outcome of a series of translocation positive SC patients. PATIENT AND METHODS: We re-evaluated the pathological diagnosis of a subset of SGCs, diagnosed in 4 of 8 Dutch head and neck centers. Subsequently, tumors with a morphological resemblance to SC were tested for the ETV6-NTRK3 fusion gene using RT-PCR. Furthermore, patients prospectively diagnosed with SC were included. The clinical characteristics and outcomes were retrieved from the patient files. RESULTS: Thirty-one patients with ETV6-NTRK3 fusion gene positive SC were included. The median age was 49 years, 17 patients (55%) were male. Eighteen tumors (58%) arose in the parotid gland. One patient presented with lymph node metastasis. All patients underwent tumor resection and 4 patients had a neck dissection. Four patients had re-resection and 15 patients (48%) received postoperative radiotherapy. One patient developed a local recurrence, no regional recurrences or distant metastases were observed. After a median follow-up of 49 months the 5- and 10-year overall survival were 95%, the 5- and 10-year disease free survival were 89%. CONCLUSION: The clinical course of SC is favorable with a low rate of locoregional recurrence and excellent survival. Given the low incidence of nodal metastases, elective neck treatment, i.e. surgery and/or radiotherapy, does not seem to be indicated.en_US
dc.format.extent29 - 33en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectETV6-NTRK3en_US
dc.subjectGene Fusionen_US
dc.subjectHead and Neck Neoplasmsen_US
dc.subjectMASCen_US
dc.subjectMammary analogue secretory carcinomaen_US
dc.subjectPrognosisen_US
dc.subjectSalivary gland neoplasmsen_US
dc.subjectSecretory carcinomaen_US
dc.titleClinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-04-26en_US
rioxxterms.versionofrecord10.1016/j.oraloncology.2018.04.022en_US
rioxxterms.licenseref.startdate2018-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfOral Oncolen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.publication-statusPublisheden_US
pubs.volume82en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical and Translational Sarcomaen_US
dc.contributor.icrauthorvan der Graaf, Wilhelminaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record